XOMA Royalty Declares Quarterly Preferred Stock Dividends
Rhea-AI Summary
XOMA Royalty (Nasdaq: XOMA) has announced quarterly cash dividends for its Series A and Series B Cumulative Preferred Stock. Holders of the 8.625% Series A Cumulative Perpetual Preferred Stock (Nasdaq: XOMAP) will receive $0.53906 per share. Holders of depositary shares for the 8.375% Series B Cumulative Perpetual Preferred Stock (Nasdaq: XOMAO) will receive $0.52344 per depositary share. The dividends will be paid on or about October 15, 2024, to holders of record as of the close of business on October 3, 2024. This announcement demonstrates XOMA's commitment to providing returns to its preferred stockholders.
Positive
- Consistent dividend payments for preferred stockholders
- Timely announcement of dividend details
- Maintenance of dividend rates for both Series A and Series B preferred stocks
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, XOMA declined 3.90%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
EMERYVILLE, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced its Board of Directors has authorized the following cash dividends to holders of XOMA’s Series A and Series B Cumulative Preferred Stock:
Holders of the
Holders of depositary shares, each representing 1/1000 of a share of XOMA’s
The preferred dividends will be paid on or about October 15, 2024, to respective holders of record at the close of business on October 3, 2024.
About XOMA Royalty Corporation
XOMA Royalty is a biotechnology royalty aggregator playing a distinctive role in helping biotech companies achieve their goal of improving human health. XOMA Royalty acquires the potential future economics associated with pre-commercial therapeutic candidates and commercial assets that have been licensed to pharmaceutical or biotechnology companies. When XOMA Royalty acquires the future economics, the seller receives non-dilutive, non-recourse funding they can use to advance their internal drug candidate(s) or for general corporate purposes. The Company has an extensive and growing portfolio with more than 70 assets (asset defined as the right to receive potential future economics associated with the advancement of an underlying therapeutic candidate). For more information about the Company and its portfolio, please visit www.xoma.com or follow XOMA Royalty Corporation on LinkedIn.
EXPLANATORY NOTE: Any references to “portfolio” in this press release refer strictly to milestone and/or royalty rights associated with a basket of drug products in development. Any references to “assets” in this press release refer strictly to milestone and/or royalty rights associated with individual drug products in development.
As of the date of this press release, the commercial assets in XOMA Royalty’s milestone and royalty portfolio are VABYSMO® (faricimab-svoa), OJEMDA™ (tovorafenib), MIPLYFFA™ (arimoclomol), XACIATO™ (clindamycin phosphate) vaginal gel
| Investor Contact Juliane Snowden XOMA Royalty Corporation +1 646-438-9754 juliane.snowden@xoma.com | Media Contact Kathy Vincent KV Consulting & Management +1 310-403-8951 kathy@kathyvincent.com |
FAQ
What is the dividend amount for XOMA's Series A Preferred Stock (XOMAP)?
What is the dividend amount for XOMA's Series B Preferred Stock (XOMAO)?
When will XOMA pay the preferred stock dividends announced on September 23, 2024?
What is the record date for XOMA's preferred stock dividends announced in September 2024?
